RAPT Therapeutics, Inc. Stock

Equities

RAPT

US75382E1091

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
7.93 USD -1.37% Intraday chart for RAPT Therapeutics, Inc. -15.46% -68.09%
Sales 2024 * - Sales 2025 * - Capitalization 280M
Net income 2024 * -129M Net income 2025 * -164M EV / Sales 2024 * -
Net cash position 2024 * 132M Net cash position 2025 * 181M EV / Sales 2025 * -
P/E ratio 2024 *
-2.58 x
P/E ratio 2025 *
-2.59 x
Employees 131
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.04%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on RAPT Therapeutics, Inc.

1 day-1.37%
1 week-15.46%
Current month-11.69%
1 month-4.80%
3 months-66.27%
6 months-32.40%
Current year-68.09%
More quotes
1 week
7.85
Extreme 7.85
9.19
1 month
7.80
Extreme 7.8
9.65
Current year
6.86
Extreme 6.86
27.35
1 year
6.86
Extreme 6.86
27.35
3 years
6.86
Extreme 6.86
43.26
5 years
6.86
Extreme 6.86
51.21
10 years
6.86
Extreme 6.86
51.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 15-07-31
Director of Finance/CFO 61 19-12-01
Chief Tech/Sci/R&D Officer - 22-05-03
Members of the board TitleAgeSince
Director/Board Member 71 19-12-03
Chairman 64 16-03-31
Director/Board Member 63 19-10-21
More insiders
Date Price Change Volume
24-04-18 7.93 -1.37% 707,678
24-04-17 8.04 -1.11% 709,603
24-04-16 8.13 -4.80% 1,240,554
24-04-15 8.54 -7.07% 1,113,617
24-04-12 9.19 -2.03% 1,187,933

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
7.93 USD
Average target price
22 USD
Spread / Average Target
+177.43%
Consensus